Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin for Heart Stress in Stage B Heart Failure: Randomized Crossover Trial
ChiCTR2500108869Phase 3Not yet recruiting
- Sponsor
- Yingde People's Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of henagliflozin in heart failure (HF) and Takotsubo cardiomyopathy (TCM) (2 arms), sponsored by Yingde People's Hospital. Primary endpoint: N-terminal pro-B-type natriuretic peptide (NT-proBNP). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
heart failure (HF)Takotsubo cardiomyopathy (TCM)
Beyond the preview
Go deeper on ChiCTR2500108869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108869.